Skip to main content
SpringerLink
Log in

APL in Developing Countries: ATO-Based Approach

  • Chapter
  • First Online:
Acute Promyelocytic Leukemia

  • 626 Accesses

Abstract

It is well recognized that arsenic trioxide (ATO) is an effective agent for the treatment of acute promyelocytic leukemia (APL). Use of single agent ATO in the treatment of APL leads to remissions which are durable in the majority, although few cases of primary resistance have been reported. The drug has been used both as a single agent and in combination with other conventional drugs to treat APL. Use of ATO is the accepted standard of care in the management of relapsed APL, where it is often used effectively as a bridge to a stem cell transplant. Currently, the combination of all-trans retinoic acid (ATRA) and ATO is considered the standard of care for newly diagnosed low- and intermediate-risk APL. ATO probably has multiple mechanisms of action. Better understanding of its mechanisms of action/s and synergy with other agents will likely lead to a more rationale use of this agent or its derivatives, either alone or in combination. There is limited data on the kinetics of leukemia clearance and normal hematopoietic recovery after the administration of single agent ATO for the treatment of APL, but preliminary data suggests that it is likely to be different from conventional therapy. There have been a number of concerns of the potential short- and long-term toxicity of this agent. Most such concerns arise from the toxicity profile noted in people exposed to long-term arsenic in the environment. The overall toxicity profile has been favorable with the therapeutic doses and schedules of administration of ATO in the treatment of malignancies. In a resource-constrained environment, the use of a single agent ATO-based regimen is a realistic and acceptable option to treat almost all patients with APL. In the developed world, it has the potential in combination with other agents to improve the clinical outcome with reduction of dose intensity of chemotherapy and remains an option for patients who would not tolerate conventional therapy. This chapter will focus on the use of single agent ATO and ATO-based non-myelosuppressive regimens as a treatment for APL, especially in a developing country.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–15.

    Article  CAS  Google Scholar 

  2. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev. 2004;30(3):237–47.

    Article  Google Scholar 

  3. Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, Willemze R, van Ineveld BM. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res. 2001;10(1):187–92.

    Article  CAS  Google Scholar 

  4. Leunis A, Blommestein HM, Huijgens PC, Blijlevens NM, Jongen-Lavrencic M, Uyl-de Groot CA. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res. 2012;37(3):245–50.

    Article  Google Scholar 

  5. Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J Intern Med. 1994;236(4):401–9.

    Article  CAS  Google Scholar 

  6. Kruse M, Wildner R, Barnes G, Martin M, Mueller U, Lo-Coco F, et al. Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective. PLoS One. 2015;10(8):e0134587.

    Article  Google Scholar 

  7. Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M, et al. Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States. Clin Lymphoma Myeloma Leuk. 2015;15(12):771–7.

    Article  Google Scholar 

  8. Wikipedia. List of countries by GNI (nominal, Atlas method) per capita: http://en.wikipedia.org/wiki/List_of_countries_by_GNI_(nominal,_Atlas_method)_per_capita; 2014 [updated 10/06/201410/15/2014]. http://en.wikipedia.org/wiki/List_of_countries_by_GNI_(nominal,_Atlas_method)_per_capita.

  9. Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India. Lancet. 2011;377(9764):505–15.

    Article  CAS  Google Scholar 

  10. Garg CC, Karan AK. Reducing out-of-pocket expenditures to reduce poverty: a disaggregated analysis at rural-urban and state level in India. Health Policy Plan. 2009;24(2):116–28.

    Article  Google Scholar 

  11. Craig BM, Rollison DE, List AF, Cogle CR. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomark Prev. 2012;21(3):474–81.

    Article  Google Scholar 

  12. Philip C, George B, Korula A, Srivastava A, Balasubramanian P, Mathews V. Treatment rates of paediatric acute myeloid leukaemia: a view from three tertiary centres in India—response to Gupta et al. Br J Haematol. 2016;175(2):347–9.

    Article  Google Scholar 

  13. Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, et al. Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol. 2015;170(1):110–7.

    Article  Google Scholar 

  14. Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–9.

    Article  CAS  Google Scholar 

  15. Kerr D. Generic drugs: their role in better value cancer care. Ann Oncol. 2013;24(Suppl 5):v5. https://doi.org/10.1093/annonc/mdt321.

    Article  PubMed  Google Scholar 

  16. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–42.

    Article  Google Scholar 

  17. Lopes GL. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol. 2013;24(Suppl 5):v13–v6.

    Article  Google Scholar 

  18. Cyranoski D. Arsenic patent keeps drug for rare cancer out of reach of many. Nat Med. 2007;13(9):1005.

    Article  CAS  Google Scholar 

  19. Warrell RP Jr. Reply to ‘Arsenic patent keeps drug for rare cancer out of reach for many’. Nat Med. 2007;13(11):1278.

    Article  CAS  Google Scholar 

  20. Jolliffe DM. A history of the use of arsenicals in man. J R Soc Med. 1993;86(5):287–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Zhang TD. Treatment of acute granulocytic leukemia with “Ai ling No. 1”—clinical analysis and experimental research. Zhong Xi Yi Jie He Za Zhi. 1984;4(1):19–20.

    CAS  PubMed  Google Scholar 

  22. Zhang PWS, Hu LH, Shi FD, Giu FQ, Hong GJ, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide injection (713): clinical observations and study of action mode. Chin J Hematol. 1996;17:58–60.

    Google Scholar 

  23. Sun HDML, Hu XC, Zhang TD. Thirty two cases of treating acute promyelocytic leukemia by Ailing I therapy combined with syndrome differentiation treatment of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med. 1992;1996(12):170–1.

    Google Scholar 

  24. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89(9):3345–53.

    CAS  Google Scholar 

  25. Tang W, Chen G, Shi G. Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line. Zhonghua Yi Xue Za Zhi. 1997;77(7):509–12.

    CAS  PubMed  Google Scholar 

  26. Chen Z, Wang ZY, Chen SJ. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther. 1997;76(1–3):141–9.

    Article  CAS  Google Scholar 

  27. Zheng X, Seshire A, Ruster B, Bug G, Beissert T, Puccetti E, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica. 2007;92(3):323–31.

    Article  CAS  Google Scholar 

  28. Ablain J, de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011;117(22):5795–802.

    Article  CAS  Google Scholar 

  29. Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A. Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis. 2012;3(1):e2011056.

    Article  Google Scholar 

  30. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354–60.

    CAS  PubMed  Google Scholar 

  31. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339(19):1341–8.

    Article  CAS  Google Scholar 

  32. Wang Z, Zhou J, Lu X, Gong Z, Le XC. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol. 2004;17(1):95–103.

    Article  CAS  Google Scholar 

  33. Sweeney CJ, Takimoto C, Wood L, Porter JM, Tracewell WG, Darwish M, et al. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010;66(2):345–56.

    Article  CAS  Google Scholar 

  34. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28(24):3866–71.

    Article  CAS  Google Scholar 

  35. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107(7):2627–32.

    Article  CAS  Google Scholar 

  36. Mathews V, Desire S, George B, Lakshmi KM, Rao JG, Viswabandya A, et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia. 2006;20(5):881–3.

    Article  CAS  Google Scholar 

  37. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29(20):2753–7.

    Article  CAS  Google Scholar 

  38. Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115(9):1697–702.

    Article  CAS  Google Scholar 

  39. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett. 2000;112–113:209–17.

    Article  Google Scholar 

  40. Goering PLAH, Mass MJ, et al. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol Sci. 1999;49:5–14.

    Article  CAS  Google Scholar 

  41. Brouwer OF, Onkenhout W, Edelbroek PM, et al. Increased neurotoxicity of arsenic in MTHFR deficiency. Clin Neurol Neurosurg. 1992;94:307–10.

    Article  CAS  Google Scholar 

  42. Pickett CB. Glutathione S-transferases: gene structure, regulation and biological function. Annu Rev Biochem. 1989;58:743–64.

    Article  CAS  Google Scholar 

  43. Chiou HY, Hsueh YM, Hseih LL, et al. Arsenic methylation capacity, body retention and null genotypes of glutathione S-transferases M1 and T1 among current arsenic exposed residents of Taiwan. Mutat Res. 1997;386(3):197–207.

    Article  Google Scholar 

  44. Naranmandura H, Carew MW, Xu S, Lee J, Leslie EM, Weinfeld M, et al. Comparative toxicity of arsenic metabolites in human bladder cancer EJ-1 cells. Chem Res Toxicol. 2011;24(9):1586–96.

    Article  CAS  Google Scholar 

  45. Zhang PWS, Hu LH, Shi FD, Giu FQ, Hong GJ, et al. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol. 1996;2:58.

    Google Scholar 

  46. Sun HDML, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med. 1992;12:170.

    Google Scholar 

  47. Treleaven J, Meller S, Farmer P, Birchall D, Goldman J, Piller G. Arsenic and ayurveda. Leuk Lymphoma. 1993;10(4–5):343–5.

    Article  CAS  Google Scholar 

  48. Mathews V, George B, Jijina F, Ross C, Nair R, Apte S, et al. Final analysis of a multi-center randomized controlled trial (IAPLSG04) to study the optimal duration of arsenic trioxide maintenance therapy in the treatment of newly diagnosed acute promyelocytic leukemia. ASH Annual Meeting Abstracts. 2011;118(21):426.

    Google Scholar 

  49. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570–80; quiz 752.

    Article  CAS  Google Scholar 

  50. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21.

    Article  CAS  Google Scholar 

  51. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–305.

    Article  CAS  Google Scholar 

  52. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29(20):2753–7.

    Article  CAS  Google Scholar 

  53. Estey E, Koller C, Cortes J, Reed P, Freireich E, Giles F, et al. Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid. Leuk Lymphoma. 2001;42(3):309–16.

    Article  CAS  Google Scholar 

  54. Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504–10.

    Article  CAS  Google Scholar 

  55. Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010;28(6):1047–53.

    Article  CAS  Google Scholar 

  56. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342–7.

    Article  CAS  Google Scholar 

  57. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med. 2000;133(11):881–5.

    Article  CAS  Google Scholar 

  58. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001;98(2):266–71.

    Article  CAS  Google Scholar 

  59. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 2001;97(5):1514–6.

    Article  CAS  Google Scholar 

  60. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315–24.

    CAS  PubMed  Google Scholar 

  61. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005;23(10):2396–410.

    Article  CAS  Google Scholar 

  62. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci U S A. 1998;95(14):8103–7.

    Article  CAS  Google Scholar 

  63. Cuzick J, Evans S, Gillman M, Price Evans DA. Medicinal arsenic and internal malignancies. Br J Cancer. 1982;45(6):904–11.

    Article  CAS  Google Scholar 

  64. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–91.

    Article  CAS  Google Scholar 

  65. Mathews V, Chandy M, Srivastava A. Arsenic trioxide in the management of acute promyelocytic leukaemia. Natl Med J India. 2001;14(4):215–22.

    CAS  PubMed  Google Scholar 

  66. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24(1):17–31.

    CAS  PubMed  Google Scholar 

  67. Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, et al. Secondary cytogenetic changes in acute promyelocytic leukemia—prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15(5):1786–95.

    Article  CAS  Google Scholar 

  68. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801–6.

    PubMed  Google Scholar 

  69. Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92(7):994–5.

    Article  CAS  Google Scholar 

  70. Gilliland DG. FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. Best Pract Res Clin Haematol. 2003;16(3):409–17.

    Article  CAS  Google Scholar 

  71. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–42.

    Article  CAS  Google Scholar 

  72. Marasca R, Maffei R, Zucchini P, Castelli I, Saviola A, Martinelli S, et al. Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with Flt3 mutational status. Leukemia. 2006;20(1):103–14.

    Article  CAS  Google Scholar 

  73. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768–76.

    Article  CAS  Google Scholar 

  74. Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19(7):1153–60.

    Article  CAS  Google Scholar 

  75. Chillon MC, Santamaria C, Garcia-Sanz R, Balanzategui A, Maria Eugenia S, Alcoceba M, et al. Long FLT3 internal tandem duplications and reduced PML-RARalpha expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica. 2010;95(5):745–51.

    Article  CAS  Google Scholar 

  76. Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009;15(11):1479–84.

    Article  CAS  Google Scholar 

  77. Ganesan S, Alex AA, Chendamarai E, Balasundaram N, Palani HK, David S, et al. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2016;30(11):2169–78.

    Article  CAS  Google Scholar 

  78. Mathews V, Korula A, Kulkarni U, Ganesan S, David S, Alex AA, Nisham PN, Abraham A, Srivastava A, Lakshmi KM, Balasubramanian P, George B. Management of relapsed acute promyelocytic leukemia post ATO upfront therapy: open-labeled phase II study evaluating role of proteasome inhibition. Blood. 2016;128(22):446.

    Google Scholar 

  79. Mathews V. De-escalation of treatment for acute promyelocytic leukaemia? Lancet Haematol. 2015;2(9):e348–9.

    Article  Google Scholar 

  80. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Christian Medical College and Hospital, Vellore, 632004, India

    Vikram Mathews M.B.B.S., M.D., D.M.

Authors
  1. Vikram Mathews M.B.B.S., M.D., D.M.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vikram Mathews M.B.B.S., M.D., D.M. .

Editor information

Editors and Affiliations

  1. Division of Hematology/Oncology, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada

    Oussama Abla

  2. Department of Hematology, University of Tor Vergata, Rome, Italy

    Francesco Lo Coco

  3. Department of Medicine, Hospital Universitari i Politecnic La Fe, University of Valencia, Valencia, Spain

    Miguel A. Sanz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Mathews, V. (2018). APL in Developing Countries: ATO-Based Approach. In: Abla, O., Lo Coco, F., Sanz, M. (eds) Acute Promyelocytic Leukemia . Springer, Cham. https://doi.org/10.1007/978-3-319-64257-4_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64257-4_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64256-7

  • Online ISBN: 978-3-319-64257-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation